SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys quarterly results beat expectations and the company raised its outlook, with record QNX performance and a major Coretura Alloy Kore design win drawing attention; traders also highlighted a reported Uber QNX selection and broader Physical AI opportunities. Many welcomed the growth prospects, while others questioned the stocks volatile, muted reaction and pointed to softer Secure Communications results and market weakness.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Pharvaris positive Phase 3 results for its oral HAE-prevention drug have intensified concern about competition for BioCrysts Orladeyo and its future market share. Bearish traders worry about longer-term revenue pressure, while bulls argue a competitor launch is still some time away and point to Orladeyos established business and BioCrysts navenibart pipeline.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons decision to block Metas Muse shopping agent is driving debate over whether AI agents could threaten its marketplace and advertising business or whether Amazon can defend its commerce position with its own agentic tools and AWS. Traders are split, with concern about Amazon falling behind alongside bullish views that the move protects its platform; many also complain that the stock has lagged peers.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is under pressure as long-term Treasury yields surge to multi-decade highs amid persistent inflation concerns, hawkish Fed expectations, and worries about government debt and bond demand. Traders are largely bearish and question whether Treasury buybacks can stem the selloff, while some see high yields as an opportunity to buy for a potential rebound; others note that equities have so far shown limited reaction.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally is being attributed by traders to reported institutional tokenization and banking developments, including a role in a tokenized-deposits network, alongside Robinhood availability. Bulls are touting QNTs limited supply and potential demand from financial institutions, while skeptics warn the move could reverse as a news-driven pump.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Optimism that Metas Muse AI agent could increase demand for CPUs in data centers is fueling AMDs sharp rally and fresh highs, alongside broader AI-chip enthusiasm. Traders are celebrating the momentum and possible short squeeze, while others warn that the valuation has run far ahead of fundamentals and expect a pullback.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is under pressure after analyst downgrades and concerns about limited booking visibility into 2026, alongside broader solar-sector weakness and policy uncertainty. Traders are split between calling the selloff excessive and buying the dip, and expecting further declines.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

ONDOs sharp rally is being linked to its expansion in tokenized investment products, particularly the launch of onchain portfolios powered by BlackRock. Traders are bullish on the RWA and institutional-adoption story, while others question whether that growth will benefit ONDO holders without a direct value-accrual mechanism.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions reported achievement of 30 entangled logical qubits on its commercial Sqale system, using 80 physical qubits, is driving attention as a quantum-computing milestone and evidence of progress toward its roadmap. Many traders see it as validation of the companys technology, while others question the significance or are disappointed that the share-price response has been muted amid market and sector headwinds.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins pullback is driving attention to Strategy, which traders view as a leveraged play on the cryptocurrencys moves. The community is split between dip buyers anticipating a rebound and bearish traders watching for further downside, with short-term support and possible short squeezes also in focus.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM),&#160;a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman &#38; Renshaw&#160;initiated&#160;coverage of the company with a Buy rating and&#160;a&#160;$8 price target. The research report was led by Michael G. King Jr., director of research and senior [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM)&#160;a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual&#160;ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)&#160;received a ‘Buy’ rating from&#160;Rodman &#38; Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous […]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;reported second-quarter 2026 financial and operational results, including a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. Combined cash, cash equivalents and digital [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and&#160;Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;is one of the companies [&#8230;]

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial

Paid Advertisement: This article is a paid promotion.  Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) is advancing on multiple fronts this summer, headlined by FDA clearance to mov...

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions. The novel imaging technique is designed to […]

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Current Price	$4.00
Prev Close	$3.88
Open	$4.00
Dividend Yield	0.00%
50-Day Moving Average	$3.28
Beta	1.23
Avg. Volume	303,432.14
PE Ratio	-0.70

52-Week High	$19.30
52-Week Low	$2.07
Market Capitalization	$31.38M
EPS (Annual)	-$7.97
Price to Book	3.81
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

QNTM Fundamentals